PharmaCell to Purchase Cell Therapy Production Facility from TiGenix

PharmaCell B.V., a CMO for cellular therapies and regenerative medicine in Europe, has entered into an agreement with TiGenix N.V. to purchase its therapy production facility at the Chemelot site in Sittard-Geleen, The Netherlands. TiGenix is a European cell therapy company with a marketed product for cartilage repair, ChondroCelect. TiGenix and PharmaCell have signed an agreement to purchase the shares of TiGenix B.V., which holds the manufacturing site, subject to certain closing conditions and intend to close the transaction in the coming months. PharmaCell will acquire the facility, including its employees in Production, QC, QA and other functions. ChondroCelect will continue to be manufactured at the facility as before under a long-term CMO agreement with PharmaCell.

Source: PharmaCell B.V.